Literature DB >> 29306047

Unified protocol for the discontinuation of long-term serotonin reuptake inhibitors in obsessive compulsive disorder: Study protocol and methods.

Christina L Boisseau1, Steven A Rasmussen2.   

Abstract

Obsessive-compulsive disorder (OCD) is chronic psychiatric disorder associated with high rates of functional impairment and decreased quality of life. Although serotonin reuptake inhibitors have demonstrated efficacy in the treatment of OCD, little data is available to guide clinicians on how to manage these medications long-term. Cognitive-behavioral approaches provide a promising avenue for helping OCD patients discontinue maintenance SRIs while minimizing the potential for symptom worsening. This manuscript describes the rationale and methods for pilot feasibility study designed to a unified, cognitive-behavioral strategy for discontinuing long-term SRIs in OCD. The aims of the study are (1) to evaluate the feasibility and acceptability of research procedures and interventions, (2) to test the efficacy of this treatment relative to an enhanced control condition and (3) to investigate the role of distress tolerance in both taper completion and clinical outcome. Our central aim is to investigate whether this approach improves discontinue outcomes relative to an enhanced control condition. Identifying optimal long-term treatment strategies for this population is needed to guide clinicians managing this often-chronic disorder.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anxiety; Medication; Obsessive compulsive disorder; Taper

Mesh:

Substances:

Year:  2018        PMID: 29306047      PMCID: PMC5803458          DOI: 10.1016/j.cct.2017.12.017

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  49 in total

1.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

Review 2.  Behaviour therapy for obsessive-compulsive disorder: a decade of progress.

Authors:  I Marks
Journal:  Can J Psychiatry       Date:  1997-12       Impact factor: 4.356

3.  Development of a rating scale for primary depressive illness.

Authors:  M Hamilton
Journal:  Br J Soc Clin Psychol       Date:  1967-12

4.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

5.  Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study.

Authors:  E Mundo; L Bianchi; L Bellodi
Journal:  J Clin Psychopharmacol       Date:  1997-08       Impact factor: 3.153

6.  Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors.

Authors:  Giuseppe Maina; Umberto Albert; Virginio Salvi; Filippo Bogetto
Journal:  J Clin Psychiatry       Date:  2004-10       Impact factor: 4.384

7.  Treatment of obsessive-compulsive disorder by U.S. psychiatrists.

Authors:  Carlos Blanco; Mark Olfson; Dan J Stein; Helen Blair Simpson; Marc J Gameroff; William H Narrow
Journal:  J Clin Psychiatry       Date:  2006-06       Impact factor: 4.384

8.  Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure.

Authors:  J Endicott; J Nee; W Harrison; R Blumenthal
Journal:  Psychopharmacol Bull       Date:  1993

9.  Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder.

Authors:  H Blair Simpson; Michael R Liebowitz; Edna B Foa; Michael J Kozak; Andrew B Schmidt; Vivienne Rowan; Eva Petkova; Kevin Kjernisted; Jonathan D Huppert; Martin E Franklin; Sharon O Davies; Raphael Campeas
Journal:  Depress Anxiety       Date:  2004       Impact factor: 6.505

10.  Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial.

Authors:  P Thorén; M Asberg; B Cronholm; L Jörnestedt; L Träskman
Journal:  Arch Gen Psychiatry       Date:  1980-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.